000 03955 am a22006013u 4500
042 _adc
100 1 0 _aChachlaki, Konstantina
_eauthor
_91494
700 1 0 _aMessina, Andrea
_eauthor
700 1 0 _aDelli, Virginia
_eauthor
_91496
700 1 0 _aLeysen, Valerie
_eauthor
700 1 0 _aMaurnyi, Csilla
_eauthor
_91498
700 1 0 _aHuber, Chieko
_eauthor
_91499
700 1 0 _aTernier, Gaëtan
_eauthor
_91500
700 1 0 _aSkrapits, Katalin
_eauthor
_91501
700 1 0 _aPapadakis, Georgios
_eauthor
_91502
700 1 0 _aShruti, Sonal
_eauthor
_91503
700 1 0 _aKapanidou, Maria
_eauthor
_91504
700 1 0 _aCheng, Xu
_eauthor
_91505
700 1 0 _aAcierno, James
_eauthor
700 1 0 _aRademaker, Jesse
_eauthor
_91507
700 1 0 _aRasika, S
_eauthor
700 1 0 _aQuinton, Richard
_eauthor
_91509
700 1 0 _aNiedziela, Marek
_eauthor
_91510
700 1 0 _aL'Allemand, Dagmar
_eauthor
_91511
700 1 0 _aPignatelli, Duarte
_eauthor
_91512
700 1 0 _aDirlewander, Mirjam
_eauthor
_91513
700 1 0 _aLang-Muritano, Mariarosaria
_eauthor
_91514
700 1 0 _aKempf, Patrick
_eauthor
_91515
700 1 0 _aCatteau-Jonard, Sophie
_eauthor
_91516
700 1 0 _aNiederländer, Nicolas J.
_eauthor
_91517
700 1 0 _aCiofi, Philippe
_eauthor
700 1 0 _aTena-Sempere, Manuel
_eauthor
700 1 0 _aGarthwaite, John
_eauthor
_91520
700 1 0 _aStorme, Laurent
_eauthor
_91521
700 1 0 _aAvan, Paul
_eauthor
_91522
700 1 0 _aHrabovszky, Erik
_eauthor
_91523
700 1 0 _aCarleton, Alan
_eauthor
_91524
700 1 0 _aSantoni, Federico
_eauthor
700 1 0 _aGiacobini, Paolo
_eauthor
700 1 0 _aPitteloud, Nelly
_eauthor
700 1 0 _aPrevot, Vincent
_eauthor
245 0 0 _aNOS1 mutations cause hypogonadotropic hypogonadism with sensory and cognitive deficits: reversal with NO therapy in infantile mice
260 _c2022-10-05.
500 _a/pmc/articles/PMC7613826/
500 _a/pubmed/36197968
520 _aBACKGROUND: The nitric oxide (NO) signaling pathway in hypothalamic neurons plays a key role in the regulation of the secretion of gonadotropin-releasing hormone (GnRH), crucial for reproduction. We hypothesized that a disruption of neuronal NO synthase (NOS1) activity underlies some forms of hypogonadotropic hypogonadism. METHODS: Whole exome sequencing was performed on a large cohort of probands with congenital hypogonadotropic hypogonadism to identify ultra-rare variants in NOS1. The activity of NOS1 mutants identified was assessed by their ability to promote nitrite and cGMP production in vitro. In addition, physiological and pharmacological characterization was carried out in a Nos1-deficient mouse model. FINDINGS: We identified 5 heterozygous NOS1 loss-of-function mutations in 6 probands with congenital hypogonadotropic hypogonadism (2%), who displayed additional phenotypes including anosmia, hearing loss and intellectual disability. In addition, NOS1 was found to be transiently expressed by newly born GnRH neurons in the nose of both humans and mice, and Nos1 deficiency in mice resulted in dose-dependent defects not only in sexual maturation but also olfaction, hearing and cognition. The pharmacological inhibition of NO production in infantile mice revealed a critical time window during which Nos1 activity shaped minipuberty and sexual maturation. Inhaled NO treatment at minipuberty rescued both reproductive and behavioral phenotypes in Nos1-deficient mice. INTERPRETATION: The lack of timely NOS1 activity causes GnRH deficiency and lifelong sensory and intellectual comorbidities in humans and mice. NO treatment during a critical window, by reversing deficits in sexual maturation, olfaction and cognition in Nos1-deficient mice, thus holds therapeutic potential for humans.
540 _a
546 _aen
690 _aArticle
655 7 _aText
_2local
786 0 _nSci Transl Med
856 4 1 _uhttp://dx.doi.org/10.1126/scitranslmed.abh2369
_zConnect to this object online.
999 _c1702
_d1702